SEC Tracker
Get the app

Editas Medicine EDIT

Editas Medicine Q3 FY23: revenue $5.3M; diluted EPS −$0.55

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Editas Medicine reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$5.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$45.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.55No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$82.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$35.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Editas Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Allogene Therapeutics ALLO public float $184M, Jun 30, 2025
  2. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  3. Inhibrx Biosciences INBX public float $175M, Jun 30, 2025
  4. Monte Rosa Therapeutics GLUE public float $212M, Jun 30, 2025
  5. Century Therapeutics IPSC public float $213M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.